Publications
5674 Results
- Journal / Conference
- Journal of Clinical Oncology Sep 17:JCO2400527. doi: 10.1200/JCO.24.00527. Online ahead of print
- Year
- 2024
- PMID
- PMID39288338
Correlative Science in the Cooperative Group System—Re-Engineering for Success
- Journal / Conference
- ESMO (September 13-17, 2024, Barcelona, Spain), poster
- Year
- 2024
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1216
Inherited variants in SRD5A genes and response to hormonal therapy in SWOG S1216
- Journal / Conference
- ESMO (September 13-17, 2024, Barcelona, Spain), mini-oral
- Year
- 2024
- Research Committee(s)
- Genitourinary
- Study Number(s)
- CTSU/A031501
Alliance A031501: AMBASSADOR study of Adjuvant Pembrolizumab (Pembro) in Muscle-Invasive Urothelial Carcinoma (MIUC) vs Observation (Obs): Extended follow-up results and metastatic disease recurrence distribution
- Journal / Conference
- ASCO Quality of Care Symposium (September 27-28, 2024, San Francisco, CA), oral
- Year
- 2024
- Research Committee(s)
- Cancer Care Delivery
Development and Validation of a Risk Prediction Model for Acute Care Use among Advanced Cancer Patients on Clinical Trials
- Journal / Conference
- Lancet Haematology Sep 30:S2352-3026(24)00276-X. doi: 10.1016/S2352-3026(24)00276-X. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Lymphoma
Radiation Target Nomenclature for Lymphoma Trials: Consensus Recommendations from the National Clinical Trials Network Groups
- Journal / Conference
- New England Journal of Medicine Oct 17;391(15):1379-1389
- Year
- 2024
- Research Committee(s)
- Lymphoma
- PMID
- PMID39413375
- PMC
- PMC11488644
- Study Number(s)
- S1826
Nivolumab-AVD or Standard of Care in Advanced Stage Classic Hodgkin Lymphoma
- Journal / Conference
- Journal for ImmunoTherapy of Cancer (JITC) Sep 28;12(9):e009128
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID39343510
- PMC
- PMC11440191
- Study Number(s)
- S1609
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Desmoid Tumors
- Journal / Conference
- JAMA Network Open Oct 1;7(10):e2437871
- Year
- 2024
- Research Committee(s)
- Genitourinary
- PMID
- PMID39374015
- PMC
- PMC11581504
- Study Number(s)
- S1216
Circulating tumor cell (CTC) count is prognostic of overall survival in metastatic hormone sensitive prostate cancer (mHSPC)
- Journal / Conference
- Clinical Cancer Research Oct 17. doi: 10.1158/1078-0432.CCR-24-0606. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID39417692
- Study Number(s)
- S1609
SWOG/NCI S1609 Phase II Basket Trial Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART): Non-Epithelial Ovarian Cancer
- Journal / Conference
- JCO Precision Oncology Nov:8:e2400287. doi: 10.1200/PO.24.00287. Epub 2024 Nov 5. 2024
- Year
- 2024
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1314